Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma.

ABSTRACT:

Background

Nivolumab is an immune checkpoint inhibitor (ICI) that selectively inhibits programmed cell death protein 1 activation, restoring antitumor immunity. ICIs are indicated for various types of advanced solid tumors; however, not all patients benefit from them, and tools that could be used in the clinic to predict response to treatment represent an unmet need. Here we describe the development of a new population pharmacokinetic (PPK) model in patients treated with nivolumab in clinical trials. Applying the model to a patient population with renal cell carcinoma identified nivolumab clearance and plasma concentration as predictors of overall survival (OS).

Methods

A custom liquid chromatography with tandem mass spectrometry method for quantifying nivolumab plasma conce

SUBMITTER: Maritaz C 

PROVIDER: S-EPMC11749330 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature